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Rice and Rice
Blast: New Bases
for Comparison
In a landmark year for agricultural genomics,
the sequences of two types of rice, Oryza sati-
va ssp. indica and O. sativa ssp. japonica, were
reported in the 5 April 2002 issue of Science.
Then, on 17 July 2002, came the announce-
ment from the National Science Foundation
that the complete genome of Magnaporthe
grisea, the fungus that causes rice blast disease,
had also been sequenced. With the complete
genome sequence of both a host and a
pathogen, scientists now have the necessary
tools to dissect the weapons of the invader
along with the defense mechanisms employed
by the host crop to withstand attack. 
Rice, which feeds half the world’s popula-
tion, was selected for sequencing because it has
the shortest genome of the economically
important grains. Data gleaned from sequenc-
ing the rice genome can be applied to other
crops—a boon to companies (such as
Monsanto and the Swiss agrochemical compa-
ny Syngenta) that are interested in developing
transgenic crops. Rice blast, which can cause
up to 20% loss in grain yield each year, was
selected because it is typical of the many fungal
pathogens that attack plants; more than 80%
of all plant diseases are caused by fungi.
“Although these sequences are specific to the
rice and rice blast genomes, they will pro-
vide a model system for understanding
host–pathogen interactions in other cereals
and staple food crops,” says Ralph Dean,
director of the North Carolina State
University Fungal Genomics Laboratory
and leader of the group that sequenced the
M. grisea genome.
A consortium of Chinese scientists led by
the Beijing Genomics Institute reported the
sequence for indica, the type of rice widely
grown in China and southern Asia, while
Syngenta carried out the sequencing of
japonica, the type grown in Japan and north-
ern Asia. All three groups used the whole-
genome shotgun sequencing method, which
decodes multiple short fragments of DNA.
The many small pieces must then be assem-
bled in proper order and located to their
respective chromosomes using bioinformatics
computer programs to predict the location of
genes on the chromosomes. 
But predictions based on computer algo-
rithms are not always accurate, says Daniel
Ebbole, an associate professor of plant pathol-
ogy and microbiology at Texas A&M
University. To test the accuracy of the bioin-
formatics-generated predictions, his lab is
sequencing expressed rice and rice blast genes
that are known to produce proteins. He is
starting with expressed sequences from RNA
isolated from the organism, which is translated
into the organism’s DNA sequence without the
intervening unexpressed sequences that are
generated in the shotgun sequencing method.
Because RNA degrades rapidly, it is not practi-
cal to sequence whole genomes using this
approach, but it is essential for validating the
accuracy of the sequences derived from the
shotgun approach.
Whereas the Chinese made the indica
sequence freely available to the public
(http://rgp.dna.affrc.go.jp/cgi-bin/statusdb/
seqcollab.pl), access to the japonica database
is restricted because Syngenta wanted to pro-
tect its commercialization exclusivity and
patent rights. This has sparked an outcry
from scientists in the public sector who feel
there should be no restrictions on data that
are published in a scientific journal. 
However, much of the japonica sequence
will be publicly available soon. The
International Rice Genome Sequencing
Project, a 10-nation consortium, is also
sequencing the japonica genome using bacte-
rial artificial chromosome libraries, a more
time-consuming but also more accurate
approach. These libraries contain DNA
pieces from each of the organism’s chromo-
somes and so allow the assignment of
sequences to their chromosomes. This, in
turn, facilitates proper alignment of the
sequence data. Project coordinators hope
that by the end of 2002, some 95% of the
japonica sequence will be available on the
public NIH-administered database GenBank
(http://www.ncbi.nlm.nih.gov/Genbank/).
Breakthroughs in genomics could eventu-
ally lead to long-term benefits to human health
and the environment, including new strategies
for reducing the use of fungicides and the cre-
ation of new chemicals that are more precise
and less toxic. Rice could be bioengineered to
augment its defense system for warding off
invasion. The genomic data could also enhance
marker-assisted selection for conventional
breeding and spark genetic engineering strate-
gies to address otherwise intractable problems.
In the meantime, there are several safe and
effective alternatives for fighting rice blast,
including planting early in the growing season,
use of resistant rice varieties, avoiding excessive
nitrogen fertilizer use, and proper flooding of
rice paddies. A project sponsored by the
Manila, Philippines–based International Rice
Research Institute and begun in 1997 involved
planting mixtures of glutinous and nongluti-
nous rice in the same fields, which virtually
eliminated rice blast in Yunnan province and
other parts of China. –Mary Eubanks
Once we can say that there are differences between people that are easily
demonstrable at the genetic level, then society will have to come to grips with
understanding diversity—and we are not prepared for that.
David Baltimore, U.S. microbiologist (1983)
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Blasting through a breakthrough. The sequencing of the genomes for rice and rice blast (inset)
offers scientists an unprecedented opportunity to compare a host and pathogen, and possibly the
means of creating more pest-resistant plants.Tracking WTC Exposures 
When the World Trade Center collapsed on
11 September 2001, thousands of people
were exposed to harmful substances
including lead, asbestos, and particulate
matter. The ATSDR and
the New York City
Department of Health and
Mental Hygiene have
joined forces to create a
registry that will identify
those people and track
their physical and mental
health to determine
whether the exposures
can be linked to any short-
or long-term adverse
health effects. FEMA is
providing $20 million to establish the registry,
which is scheduled to begin collecting data in
late 2002 or early 2003. Officials hope to have
the initial data compiled by the end of 2003. 
Global Rules for GM Foods
Members of the Codex International Task
Force on Foods Derived from Biotechnology
agreed at their March 2002 meeting that
genetically modified foods should be subject
to premarket safety assessments on a case-by-
case basis, and that nations should be
allowed to trace such foods as part of their
risk management strategies. Tracing systems
give regulators the ability to withdraw such
products from the market if they are later
found to cause adverse health effects. The
agreement bolsters efforts by the European
Union to introduce tracing systems and will
be submitted for adoption to the Codex
Alimentarius Commission at its July 2003
meeting. The commission sets voluntary but
highly influential international standards for
all areas of food production and regulation.
Sequencing Streptomyces
In the 9 May 2002 issue of Nature, a team of
British and Taiwanese scientists announced
they had completed sequencing the genome
of Streptomyces coelicolor.
The streptomycetes,
common soil bacteria, 
are used to produce anti-
tumor agents, immuno-
suppressants, and more
than two-thirds of all
naturally derived
antibiotics. The largest
bacterial genome
sequenced to date with
7,825 genes, S. coelicolor is related to the
bacteria that cause tuberculosis, leprosy, and
diphtheria. Genome data gathered for this
project are already being used to help better
understand these related bacteria, as well as
aid in the development of new drugs to help
counter the spread of antibiotic resistance.
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edited by Erin E. Dooley
Smoking Inflames
Joints
After years of researching the effects that
cigarette smoking has on rheumatoid
arthritis, Derek Mattey has some advice,
especially for women: Don’t start smoking!
In his most recent research, Mattey, a sen-
ior scientist at the Staffordshire
Rheumatology Centre in Stoke-on-Trent,
England, determined
that if a woman has
ever smoked ciga-
rettes, even if she has
since quit, she is
more likely to have a
more severe form of
rheumatoid arthritis
than women who
have never smoked.
This is especially true
if she, like millions of
other people, lacks a
key gene.
“This is an im-
portant study,” says
John Klippel, medical
director of the Atlan-
ta, Georgia–based
Arthritis Foundation.
“It confirms that cig-
arette smoking plays
a role in rheumatoid
arthritis.” Klippel
says the suggestion
of a genetic role in the severity of rheuma-
toid arthritis also makes Mattey’s work
important for understanding how the dis-
ease begins and progresses.
Mattey and his colleagues, reporting in
the March 2002 issue of Arthritis &
Rheumatism, say that the reason why smok-
ing increases the severity of the disease
appears to hinge on the relationship
between smoking, rheumatoid arthritis, and
glutathione  S-transferase M1 (GSTM1).
This enzyme helps convert environmental
toxicants, such as those found in cigarette
smoke, to less toxic, more hydrophilic prod-
ucts that can be more easily metabolized
and excreted. About half of all people lack
the GSTM1 gene, Mattey says, making it a
very common polymorphism. But the bad
news for women smokers is that lacking the
GSTM1 gene and having rheumatoid
arthritis combines for a more debilitating
course of the disease.
The researchers used polymerase chain
reaction genotyping to determine who
among 164 women with rheumatoid
arthritis had the GSTM1 gene. They also
tested the women for rheumatoid factor, an
immune complex found in the blood and
synovial fluid of patients with rheumatoid
arthritis. About 80% of patients with
rheumatoid arthritis test positive for
rheumatoid factor, and the level of rheuma-
toid factor correlates positively with the
severity of the disease. The women under-
went radiologic tests to determine the
extent of their rheumatoid arthritis damage
(their “Larsen score”), and took the Health
Assessment Questionnaire to determine
how the disease had
affected their capac-
ity to perform com-
mon activities of
daily living. 
The researchers
found that 58.5%
of the women did
not have the
GSTM1 gene. They
also ascertained that
51.3% of the wo-
men had never
smoked, and 29.9%
were  current smok-
ers. Women who
lacked the GSTM1
gene and had ever or
currently smoked
were  three times
more likely to be
rheumatoid factor
positive than wo-
men who lacked the
gene and had never
taken up cigarettes. Patients who lacked the
GSTM1 gene and had ever smoked also had
significantly higher Larsen and Health
Assessment Questionnaire scores than did
those who lacked the gene and had never
smoked.
“We were able to show that the combi-
nation of smoking and lack of the GSTM1
gene was correlated with a greater likelihood
to be rheumatoid factor positive, and the
questionnaires and radiology studies con-
firmed that these same individuals have
more advanced, more severe rheumatoid
arthritis,” Mattey says. 
The researchers aren’t sure which smoke
toxicants are responsible, or how they work.
They are now trying to determine if smok-
ing somehow induces the production of
rheumatoid factor, and if ambient cigarette
smoke also impacts rheumatoid arthritis. “It
is difficult to say from this study if second-
hand smoke has an effect on the severity of
rheumatoid arthritis,” Mattey says. “We are
trying to make that determination at the
moment.” –Ed Susman
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ENVIRONMENTAL DISEASE
Pointing the finger. New data confirm that
smoking has a hand in the development of
severe rheumatoid arthritis in women.
Streptomyces coelicolorA
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Profiles in Cancer
Historically, pathologists have struggled to
distinguish many of the 50-plus sarcoma sub-
types, which often look similar under a
microscope. Misidentification could hamper
treatment—an oncologist who doesn’t realize
a tumor is aggressive, for example, might treat
it too conservatively, allowing it to spread.
Now, however, genetic profiling of several of
the most common sarcomas—similar to the
DNA fingerprinting used to identify crimi-
nals—may enable pathologists to accurately
diagnose most soft-tissue sarcomas. 
Soft-tissue sarcomas are rare; about 8,700
new cases are diagnosed each year. Soft-tissue
sarcomas rank among the deadliest cancers,
with a five-year survival rate of about
50%. Studies have implicated Agent
Orange and other dioxin exposures.
Some cases have been associated with
therapeutic radiation, others with
workplace exposure to vinyl chloride
(used, for example, to produce plas-
tics). Most sarcomas, however, have no
known cause.
“Because sarcomas are rare, most
pathologists don’t see many of them,”
says Matt van de Rijn, an associate pro-
fessor of pathology at Stanford
University School of Medicine. “This
[technology] will increase our ability to
diagnose sarcomas.” Van de Rijn and
his colleagues published a study of sar-
coma profiling in the 13 April 2002
issue of The Lancet. Other researchers are con-
ducting similar sarcoma studies at Memorial
Sloan-Kettering Cancer Center, the University
of Minnesota, the University of Utah, and sev-
eral institutions in Europe. At the 38th annual
meeting of the American Society of Clinical
Oncology in May 2002, the Sloan-Kettering
team presented research in which they devel-
oped DNA expression profiles that can be used
to accurately diagnose nine soft-tissue sarcoma
subtypes, representing approximately 70% of
these cancers.
To develop such profiles, researchers use a
gene-expression microarray, or “gene chip.”
The chip contains thousands of known gene
samples printed onto a quartz wafer in tiny
dots. When a gene in a study cell matches one
on the chip, it binds tightly, like two pieces of
a puzzle. The cellular material causes the
matched gene dot to light up. A computer
than analyzes the pattern of luminescent genes
that make up the cell’s profile.
The profiling technique can potentially
improve the prognosis for countless patients
with more common forms of cancer. “This is a
very general technique that will have ramifica-
tions for all types of cancer, including the more
common ones such as lung, breast, colon, and
prostate,” says Robert Maki, a medical oncolo-
gist and investigator in the Sloan-Kettering
work. “All the common cancers are being
investigated.” Scientists from the National
Human Genome Research Institute and Lund
University in Sweden reported in the 1 June
2001 issue of Nature Medicine that they used
genetic profiling to distinguish four childhood
cancers that look similar under a microscope:
neuroblastoma, rhabdomyosarcoma, non-
Hodgkin lymphoma (Burkitt lym-
phoma), and Ewing sarcoma. 
Profiling may eventually help
oncologists select the best drugs for
treatment. For example, the gene
ERCC1 is associated with resistance to
cisplatin, a key drug used in treating
ovarian cancer. Oncologists who know
that a patient expresses the ERCC1
gene would choose other drugs.
Pharmaceutical researchers also can use
this information in drug development
to design new chemotherapy drugs that
disable drug-resistant genes or target
susceptible genes. “If we can identify
[genetic] targets,” says Maki, “we may
be able to develop drugs that attack
those targets.” –Cynthia Washam
MOLECULAR BIOLOGY
Jumpstarting DNA Repair
Every day, your DNA suffers damage—ultraviolet radiation, pollution,
and cigarette smoke all take their toll. If unchecked, this damage can pro-
duce more extensive DNA lesions that result in tumors. Fortunately,
DNA continuously repairs this damage. Now, for the first time, scientists
have identified a protein that senses DNA damage from ultraviolet radi-
ation and may trigger the repair process, known as the DNA damage
checkpoint system.
A team from the University of North Carolina at Chapel Hill have
found that a protein named ATR directly binds to DNA. Their study,
published in the 14 May 2002 issue of Proceedings of the National
Academy of Sciences, adds to scientists’ broad knowledge about cancer and
how cells protect themselves from DNA damage. “The DNA damage
checkpoint system is really what determines cell death or survival, in both
normal cells and cancerous cells,” says principal investigator Aziz Sancar,
a professor of biophysics and biochemistry. “ATR is a key protein in
understanding this system.” 
Scientists already knew that ATR was somehow involved in the
damage checkpoint system, but some had speculated that an interme-
diary protein actually sensed the damage. “We demonstrated that,
without an intermediary, ATR binds to DNA, and when there is DNA
damage [ATR] binds with higher affinity,” says Sancar. “It is the first
biochemistry paper showing that this protein has affinity for damaged
DNA and can sense the damage directly.” 
The researchers purified ATR from human connective tissue cells,
then mixed the purified ATR with both damaged and undamaged DNA.
They then measured the binding using different methods of biochemical
analysis as well as electron microscopy. In one method, the researchers
bound the ATR to carbohydrate beads, added radiolabeled DNA,
washed the beads three times to eliminate unbound DNA, and then visu-
alized the ATR-bound DNA by autoradiograph. Measuring the radioac-
tivity indicated the amount of DNA bound to the ATR. The findings all
showed that ATR bound directly to DNA, and bound with twice the
affinity to damaged DNA. 
The authors call the twofold difference in binding modest, but Jim
Drummond, an assistant professor of biology at Indiana University
Bloomington who specializes in the mechanisms of DNA repair path-
ways, says that small differences found during in vitro experiments can be
significant in vivo. “When you look in the cell, those sort of small [DNA-
level] differences can be amplified into very large [organism-level] differ-
ences,” he says. 
According to Drummond, the next logical step is to identify the spe-
cific sequence of cellular signals that make up the checkpoint system—
how ATR’s binding to damaged DNA results in a change in the cell cycle
and the actual repair of the DNA. Understanding that sequence could
eventually provide researchers with clues to possible gene targets for
drugs or other therapies. –Angela Spivey
GENETIC RESEARCH
The profiler. Scientists are using microarrays to develop genetic
profiles of several common sarcomas in hopes of better diagnoses.T
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The Beat
Toxicogenomics focuses on determining the role that genes play in
biological responses to environmental toxicants and stressors. This
new scientific discipline has sprung from the dramatic progress being
made in numerous genome sequencing projects and the advances
taking place in genomic technologies for expression profiling of
mRNAs and proteins.
In January 2003, Environmental Health Perspectives (EHP) will
launch a new quarterly edition, EHP Toxicogenomics. A  complemen-
tary website, located at http://ehp.niehs.nih.gov/txg/, brings
together vital information being generated in this emerging field.
In addition to housing the online version of EHP Toxicogenomics,
the site will also feature additional scientific resources such as data
sets and supplementary materials, to provide the essential infor-
mation needed to keep up to date in this fast-evolving field.
EHP Toxicogenomics will include the latest original peer-
reviewed research from the related disciplines of toxicogenomics,
pharmacogenomics, metabolomics, proteomics, and translational
aspects of genomic research, as well as commentaries and news
articles. The Call for Papers link on the homepage allows visitors to
access EHP’s instructions for authors and provides an address for
electronic submissions.
Readers can also retrieve articles relating to toxicogenomics
published in the monthly edition of EHP through the Other EHP
Articles on Toxicogenomics link. This link leads to a list of editori-
als and news articles published over the past two years, and will be
updated as new articles are published. 
EHP Toxicogenomics editor Ken Ramos, a molecular toxicolo-
gist at Texas A&M University, is introduced on the site, as are the
seven associate editors, leading scientists in the fields of computa-
tional biology, informatics, genomics, molecular medicine, and
proteomics. The site also introduces the 21-member editorial
review board, which will oversee the journal’s peer-review process. 
With its expertise in closely related areas such as toxicology,
exposure assessment, and microarray technology, the NIEHS has
been at the forefront of toxicogenomics. June 2000 saw the launch
of the National Center for Toxicogenomics, which will oversee
work at cooperating research institutions through a grants consor-
tium program. Links to the websites for both the center and the
grants consortium are posted on the EHP Toxicogenomics home-
page. –Erin E. Dooley
London Trams to Ease 
Traffic Woes
Traffic-choked areas of central London will
receive two public tram routes as part of that
city’s ongoing efforts to reduce traffic and air
pollution. The May 2002
announcement of the routes,
which are expected to cost
approximately £500 million
and transport almost 125
million passengers each year,
follows the success of a tram
route in London’s southern
suburbs that opened in May
2000. On that route, 19% of
tram riders formerly drove
automobiles. Electric-powered trams, which are
seeing a renaissance in cities around the world,
produce less noise and less air pollution than
more conventional modes of transportation. 
Six Selected for Sequencing
In May 2002, the National Human Genome
Research Institute designated six organisms as the
next group to be considered for genome
sequencing once capacity becomes available. The
chicken, the chimpanzee, several species of fungi,
the honeybee, the sea urchin, and the protozoan
Tetrahymena thermophila were selected based,
among other factors, on their importance to
medical, biological, and evolutionary studies. By
comparing the DNA sequences of a wide variety
of organisms to that of humans, scientists hope to
find the roots of many human diseases. 
Of Mice and Gen
An advanced draft of the mouse genome was
made publicly available in early May 2002 by the
Mouse Genome Sequencing Consortium, funded
in part by the NIH. Comparing the mouse
genome to the human genome will allow
scientists to identify genetic information that has
been preserved across species over hundreds of
millions of years and that is therefore
functionally important to both
species. This, in turn, could
lead to the identification
of genetic contributors to
human illnesses and the
discovery of key regul-
atory elements in the
human genome. The
project also stimulated
the development of two
computer algorithms for
assembling large genomes, tools that will be
extremely useful in looking at the genomes of
other species.
EHP Toxicogenomics
ehponline.org